Skip to Content
Søg Menu
16 – 18. februar 2023

Vi dækkede ASCO GU 2023 | Genitourinary Cancers Symposium

Nyheder fra ASCO GU 2023

Inverse correlation between natural killer cell and treatment with enzalutamide

  • / Ahmed H. Zedan
Simon Crabb

CAPItello-280 trial aims to confirm findings from ProCAID trial.

/ Simon Crabb
ASCOGU23Prostatacancer Play the Video
Aristotle Bamias

IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy

/ Aristotle Bamias
ASCOGU23 Play the Video

Novel intra-vesical drug delivery system, TAR-200, to be assessed in patients with high-risk non-muscle-invasive bladder cancer

/ BestPractice Nordic
ASCOGU22Blærecancer

Nyt studie med dansk deltagelse tester abemaciclib til patienter med metastatisk mCRPC

/ BestPractice Nordic
ASCOGU22Prostatacancer

Gå ikke glip af det nyeste fra Onkologi

Skriv dig på og modtag nye artikler, MEDtalks, MEDcast, faglige test og magasiner

Send mig seneste nyt fra onkologi

ASCO GU 2022

Bone mineral density in patients with castration-sensitive prostate cancer treated with abiraterone

/ Guilhem Roubaud
ASCOGU22Prostatacancer Play the Video
Kim Nguyen Chi

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

/ Kim Nguyen Chi
ASCOGU22Prostatacancer Play the Video
Redas Trepiakas

CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer

/ Redas Trepiakas
ASCOGU22Prostatacancer Play the Video
Daniel P. Petrylak

Promising neoadjuvant antitumor activity for patients with muscle-invasive bladder cancer

/ Daniel P. Petrylak
ASCOGU22Blærecancer Play the Video
Simon Crabb

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma

/ Simon Crabb
ASCOGU22Blærecancer Play the Video

Deep PSA declines with apalutamide is associated with lower risk for worsened QoL

/ BestPractice Nordic
ASCOGU22Prostatacancer
Fred Saad

Significant effect of PARP-inhibitor olaparib plus abiraterone in patients with mCRPC

/ Fred Saad
ASCOGU22Prostatacancer Play the Video

Nivolumab plus cabozantinib as first-line treatment for patients with aRCC – Final results 

/ BestPractice Nordic
ASCOGU22Nyrecancer

PARP inhibitor niraparib as first-line treatment in patients with prostate cancer

/ BestPractice Nordic
ASCOGU22Prostatacancer

Se tidligere dækning

Differentiering af patienter med prostatacancer i forhold til respons

/ Mads Daugaard
ProstatacancerASCO GU21 Play the Video

Nyt studie ændrer den fremtidige behandling af prostatacancer

/ Mads Daugaard
ProstatacancerASCO GU21 Play the Video

Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events

/ Arlene O. Siefker-Radtke
BlærecancerASCO GU21 Play the Video

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with first-line nivolumab plus cabozantinib

/ David Cella
NyrecancerASCO GU21 Play the Video
Flere

Vi dækkede ASCO 2020

ICI-based treatment as first-line therapy improves outcomes in patients with nccRCC

/ BestPractice Nordic
ASCOGU22Nyrecancer

Skandinavisk studie viser lovende resultater for patienter med småcellet lungecancer

/ Peter Meldgaard
ASCO20LungecancerKemoterapi

Targeteret førstelinjebehandling giver opløftende resultater for patienter med ALK-positiv NSCLC

/ Peter Meldgaard
NSCLCASCO20Lungecancer

Overbevisende effekt af osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

/ Peter Meldgaard
NSCLCASCO20Lungecancer
Mere indhold fra ASCO 2020
Back to top